Combretastatin A1 Phosphate

AGOURA HILLS, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a clinical-stage biopharmaceutical company developing drugs for the treatment of orphan oncology indications, as well as antisense and small molecule injectable drugs for the treatment of cancer, today announced its financial results for the fiscal year ended December 31, 2025 (“FY 2025”), as compared to the fiscal year ended December 31, 2024 (“FY 2024”). The financial results are based on the 2025 Annual Report on Form 10-K (“Form 10-K”) as filed with the Securities and Exchange Commission (“SEC”) on April 15, 2026. The Company recorded net income after tax of approximately $249.0 million, compared to a net loss of approximately $4.8 million in the prior year. The net income was primarily driven by a non-cash increase in the estimated fair value of the Company’s investment in GMP Biotechnology Limited (“GMP Bio”), its joint venture (“JV”), of approximately $365.4 million, as determined by an independent third-party ASC-compliant valuation, partially offset by a deferred income tax provision of approximately $111.6 million. Highlights for FY 2025 and thereafter: 2025 marked a transformational year for Oncotelic, highlighted by the successful completion of its first combination immunotherapy trial, the formalization of Sapu Bio and Sapu Nano, subsidiaries of GMP Bio, in which the Company has 45% equity interests. Additional achievements included dedicated development platforms, expansion of the Company’s AI-enabled research capabilities, and continued advancement of its joint venture programs. Joint Venture Valuation and Investment In November 2025, the Company recorded a non-cash increase in the fair value of its investment in GMP Biotechnology Limited based on an independent third-party valuation, resulting in a gain of approximately $365.4 million and a carrying value of approximately $388.0 million. This increase reflects estimated development progress and market-based assumptions and does not represent product revenue or cash received. A corresponding deferred income tax liability of approximately $111.6 million was recorded. Sapu Bio and Sapu Nano: Dual-Platform Strategy During 2025, GMP Bio formalized its two primary subsidiaries. Sapu Bio concentrates on OT-101 (TGFβ2 antisense) clinical development, regulatory advancement, and biomarker-driven positioning. Sapu Nano serves as the dedicated nanomedicine arm of the JV, advancing the Deciparticle™ platform into clinical-stage assets, partnerships, and commercialization. Together they form a diversified and scalable development platform. Deciparticle™ Nanoparticle Platform The Deciparticle™ platform utilizes ultra-small amphiphilic constructs (below ~20 nanometers) enabling enhanced tumor penetration and distribution. The JV is advancing six candidates: Sapu-001 (paclitaxel), Sapu-003 (everolimus), Sapu-004 (carboplatin), Sapu-005 (palbociclib), and Sapu-006 (docetaxel), in addition to OT-101. Everolimus formulation development is complete with a global clinical trial enrolling in Australia. Palbociclib and docetaxel INDs are expected in 2026. The platform is protected by more than 15 patent families. OT-101 Clinical Program In March 2025, we completed a Phase 1 clinical trial (NCT04862767) evaluating OT-101 in combination with IL-2 in Seoul, South Korea for advanced or metastatic solid tumors. The combination showed a tolerable safety profile with no unexpected safety signals. The JV plans to advance OT-101 plus IL-2 into further studies exploring synergies with checkpoint inhibitors such as PD-1 blockers. Separately, the JV initiated a Phase 2/3 trial for OT-101 in pancreatic cancer and is actively enrolling participants. Over ten patent families have been filed related to TGFβ2 as a prognostic indicator for cancer survival. PDAOAI (“AI”) Platform PDAOAI, the Company’s proprietary AI-enabled knowledge platform, was significantly expanded during 2025 into a core infrastructure layer supporting research, biomarker discovery, and regulatory documentation. By late 2025, PDAOAI evolved into a large-scale knowledge platform built around a TGF-β-centric biomedical corpus of over 100,000 curated abstracts with semantic retrieval and cross-referencing capabilities. PDAOAI contributed to at least seven peer-reviewed publications during 2025 across biomarker discovery, tumor microenvironment analysis, nanoparticle drug delivery, and clinical outcome correlations — spanning ovarian, breast, pancreatic, hepatocellular, and glioblastoma tumor types. Notably, the Company identified a novel biomarker signature (High RICTOR / Low RPTOR) predictive of sensitivity to intravenous everolimus based on analysis of over 9,000 tumor samples. GMP Manufacturing Facility The JV’s GMP manufacturing facility in San Diego continued full-scale operations during 2025 under its Drug Manufacturing License from the State of California. The facility utilizes a streamlined “one-pot” manufacturing process for bulk drug production through to finished product, with capabilities for both nonclinical and Phase 1 clinical trial material production. In early 2025, the Company partnered with Shanghai Medicilon, Inc. to access its rapid IND development platform supporting up to 20 IND projects. Results of Operations Below is a presentation of our financial results comparing FY 2025 to FY 2024 and based on our results published in our Form 10-K filed with the SEC on April 15, 2026. FY 2025 compared to FY 2024 Financial Results Overview ONCOTELIC THERAPEUTICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS For the Year Ended December 31, 2025 2024 Operating expenses: Research and development $4,357 $- General and administrative 3,182,242 376,013 Goodwill impairment (See note 2 and 3) - 3,200,000 Total operating expenses 3,186,599 3,576,013 Income/(Loss) from operations (3,186,599) (3,576,013)Other income (expense): Change in fair value of investment in GMP Bio 365,346,775 - Interest expense, net (885,488) (857,723)Reimbursement for expenses - related party - 22,937 Change in fair value of derivative on debt 353,572 (280,402)Loss on debt conversion (1,058,976) (88,258)Miscellaneous income 5,631 - Total other income (expense) 363,761,514 (1,203,446)Net income (loss) before income taxes 360,574,915 (4,779,459)Provision for income taxes (111,550,000) - Net income (loss) after income taxes 249,024,915 (4,779,459)Net income (loss) before non-controlling interests 249,024,915 (4,779,459)Net loss attributable to non-controlling interests (254,917) (255,527)Net income (loss) attributable to Oncotelic Therapeutics, Inc. $249,279,832 $(4,523,932) Basic net income (loss) per share attributable to common stock $0.59 $(0.01)Basic weighted average common stock outstanding 421,045,524 404,396,473 Basic and diluted net income (loss) per share attributable to common stock $0.59 $(0.01)Basic and diluted weighted average common stock outstanding 422,234,747 404,396,473 We recorded a higher net income per basic share of $0.59 for the year ended December 31, 2025, as compared to net loss per basic share of $0.01 for the year ended December 31, 2024. The Company had no product revenue for either period. We recorded net income of approximately $249.3 million attributable to Oncotelic Therapeutics, Inc. for the year ended December 31, 2025, compared to a net loss of approximately $4.5 million for the year ended December 31, 2024. The higher net income was primarily due to recording a non-cash increase in the estimated fair value of our investment in GMP Bio of approximately $365.3 million, based on an independent third-party ASC-compliant valuation. This non-cash gain was partially offset by a provision for deferred income taxes of approximately $111.6 million, higher general and administrative expenses of approximately $2.8 million primarily driven by stock-based compensation of approximately $2.4 million incurred for common stock and preferred stock issued in connection with services and approximately $0.2 million to settle litigation related to an ex-employee, higher loss on conversion of debt of approximately $1.0 million, partially offset by a favorable change in the value of derivatives on debt of approximately $0.6 million and lower interest expense of approximately $28 thousand. All operational costs associated with OT-101 and the nanoparticle platform are substantially covered by the JV, significantly reducing our direct financial burden until such time we make a determination to commence development of our own compounds. “The independent third-party valuation of our JV’s pipeline represents a significant milestone for the Company and validates the strategic investments we have made since forming the joint venture in 2022. With the successful completion of our Phase 1 OT-101/IL-2 combination trial, the advancement of six Deciparticle™ nanoparticle candidates into various stages of development, and the continued expansion of our PDAOAI platform which contributed to seven peer-reviewed publications this year, the underlying value drivers are tangible and progressing. We are now focused on the next phase of value realization — advancing the JV toward a potential Hong Kong IPO, pursuing a national exchange uplisting for the Company, and converting our pipeline progress into clinical and commercial milestones,” said Vuong Trieu, CEO of Oncotelic. “The progress made by the Company, through GMP Bio, the joint venture with Dragon, over such a short period of time is very impressive. We expect to continue to see significant progress and shareholder value creation by the Company through our ownership in GMP Bio,” said Amit Shah, CFO of Oncotelic. About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic conducts business activities through Oncotelic and its wholly-owned subsidiaries, Oncotelic, Inc., a Delaware corporation, PointR Data, Inc. (“PointR”), a Delaware corporation, Pet2DAO, Inc., a Delaware corporation; and EdgePoint AI, Inc. (“Edgepoint”), a Delaware Corporation for which there are non-controlling interests, (Oncotelic, Oncotelic Inc., PointR, Pet2DAO and Edgepoint are collectively called the Company). The Company is currently developing OT-101, in addition to five additional compounds, for various cancers and COVID-19 through its joint venture GMP Bio, with Dragon, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. In addition, GMP Bio is developing 5 additional nanoparticle compounds in the JV, which has the potential of significant revenues and value. The Company also acquired apomorphine for Parkinson’s Disease, erectile dysfunction and female sexual dysfunction. In addition, the Company is evaluating the further development of its product candidates OXi4503, as a treatment for acute myeloid leukemia and myelodysplastic syndromes, and CA4P, in combination with a checkpoint inhibitor for the treatment of advanced metastatic melanoma. The Company is also planning to address the animal health industry through Pet2DAO. Our principal corporate office is in the United States at 29397 Agoura Road, Suite 107, Agoura Hills, CA 91301 (telephone: 650-635-7000). Our internet address is www.oncotelic.com. Oncotelic’s Cautionary Note on Forward-Looking Statements Any statements contained in this Press Release that are not statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “assumption” or the negative of these terms or other comparable terminology. Statements concerning: our expectations on the timing, success of the JV’s product approvals, commercialization of the JVs products and results of operations of the JV: our expectations on the timing, success, or valuation our JV’s planned initial public offering; the timing, success or continuing valuation of our equity interest in the JV; our ability to secure future debt or equity financing needed to meet operating costs; the timing, costs and other limitations involved in obtaining regulatory approval for any product candidate; the expected efficacy of our product candidates compared to competitive products; anticipated results of our research and development programs as well as preclinical and clinical trials; expected market size, market acceptance for our product candidates; our ability to enter into future partnerships, joint ventures or other corporate transactions, ability of us being able to obtain additional resources, including debt or equity funding, and the expected benefits to be derived from those transactions; the anticipated impact of regulatory and legislative changes in the United States and foreign countries on our product candidates and operations; anticipated trends in revenues, operating expenses or financial position and results of operations; and our estimates regarding anticipated operating income or losses, future performance, future revenues and projected expense; are all forward-looking statements. Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results discussed or implied in the forward-looking statements. Factors that might cause such differences include, but are not limited to, the factors included in “Risk Factors,” in our Form 10K and the other registration statements and reports that we file with the SEC. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. We undertake no obligation to update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements. This press release may also include market data related to our business and industry. These market data may include projections that are based on a number of assumptions. While we believe these assumptions to be reasonable and sound as of the date of this press release, if these assumptions turn out to be incorrect, actual results may materially differ from the projections based on these assumptions. As a result, the markets for our product candidates may not grow at the rates projected by these data, or at all. The failure of these markets to grow at these projected rates may have a material adverse effect on our business, results of operations, financial condition and the market price of our common stock. In addition, the Company expects to remeasure the fair value of its investment in GMP Biotechnology Limited on a quarterly basis in accordance with applicable accounting standards, including Accounting Standards Codification (“ASC”) 820, Fair Value Measurement. Such remeasurements are based on significant estimates and assumptions, including clinical development progress, regulatory milestones, market conditions, and comparable company data. As a result, the value of this investment, and the corresponding impact on the Company’s financial statements, may fluctuate materially from period to period, including based on the success or failure of drug development activities within the joint venture pipeline. These fluctuations are non-cash in nature and may not be indicative of the Company’s underlying operating performance or future cash flows. Investor & Media ContactOncotelic Therapeutics, Inc.Investor Relationsir@oncotelic.com Corporate CommunicationsIBNAustin, Texaswww.InvestorBrandNetwork.com512.354.7000 OfficeEditor@InvestorBrandNetwork.com

Tips:亲爱的朋友，微信推送规则一直在变化。如果你仅仅是“关注”，很可能无法收到推送。马上操作点击“小宠物保护”公众号名片，设为星标，就可以不错过文章啦。 一、引言：认识犬急性胰腺炎——一个被低估的致命威胁 犬急性胰腺炎是一种以胰腺组织自身消化和炎症反应为特征的急腹症，是伴侣动物中最常见的消化系统危重症之一。该病起病急骤，临床表现多样且非特异，常因误诊或延误治疗而导致病情迅速恶化，甚至引发多器官功能衰竭，具有较高的发病率与死亡率。 在中国，随着宠物饲养数量的增长及饮食结构的变化，犬急性胰腺炎的疾病负担日益凸显。区域性流行病学调查显示，太原市宠物犬数量已超过50万只，其胰腺炎总体发病率达约5%[补充搜索]。值得注意的是，该病在春季和秋季呈现高发趋势，且贵宾犬、迷你雪纳瑞、腊肠犬等品种因遗传易感性而更易患病[补充搜索]。此外，长期高脂饮食、肥胖以及内分泌疾病（如糖尿病、甲状腺机能减退）等因素共同构成了主要诱因，其中饮食不当被认为是占比超75%的核心风险因素[补充搜索]。 尽管支持疗法不断进步，但传统治疗手段多集中于对症处理，缺乏针对炎症核心机制的有效干预措施。在此背景下，靶向抗炎药物PANOQUELL®-CA1（注射用夫扎普拉迪钠）的出现，标志着犬急性胰腺炎治疗进入了精准调控的新阶段。该药通过选择性抑制白细胞功能相关抗原1（LFA-1），从源头阻断中性粒细胞介导的“炎症风暴”，为改善预后提供了全新的解决方案。二、疾病本质与临床挑战（一）什么是犬急性胰腺炎？ 犬急性胰腺炎是指由于各种原因导致胰酶在胰腺内异常激活，进而引发胰腺自身消化、水肿、出血乃至坏死的一种急性炎症性疾病。根据病理严重程度，可分为轻度水肿型和重度坏死型两大类。前者以间质水肿为主，预后相对良好；后者则伴有广泛的胰腺实质坏死及周围脂肪组织皂化，极易并发全身炎症反应综合征（SIRS）、休克、呼吸窘迫等危重并发症，死亡率显著升高。 该病的常见诱发因素复杂多样，主要包括：饮食因素 ：暴饮暴食、摄入高脂肪食物（如人类剩菜、肥肉、油炸食品）是最主要的可预防诱因。代谢紊乱 ：肥胖、高脂血症、糖尿病、甲状腺机能减退等均可影响脂肪代谢，增加发病风险。遗传与品种易感 ：迷你雪纳瑞、贵宾犬、可卡犬、腊肠犬等品种存在明确的遗传倾向，部分可能与SPINK1基因突变有关[补充搜索]。其他疾病继发 ：胆道疾病（胆管炎、胆结石）、十二指肠液反流、感染性疾病（如犬瘟热、巴贝斯虫病）及某些药物使用也可能触发本病。（二）诊断难点与进展 犬急性胰腺炎的临床症状极为非特异性，典型表现为呕吐、厌食、精神沉郁、腹痛（常呈“祈祷”姿势）、脱水、腹泻甚至发热。这些症状极易与胃肠炎、肝病、肾病等多种腹部疾病混淆，仅凭临床观察难以确诊。 实验室检测方面，犬胰腺脂肪酶免疫反应活性（cPLI）已被公认为诊断金标准。当Spec cPL或SNAP cPL检测值≥400 μg/L时，结合临床症状即可高度怀疑急性胰腺炎[PANOQUELL®-CA1中文.pdf]。然而，在中国基层诊疗机构中，cPLI检测尚未实现全面普及，检测成本与设备限制使得许多病例仍依赖常规生化指标进行推断，影响了早期识别率。 影像学技术的进步为无创诊断带来了突破。近年来，农业农村部批准发布的《犬急性胰腺炎超声诊断技术》（NY/T 4824—2025）行业标准，首次系统规范了该病的超声检查流程与判读标准。该标准明确提出“四联征”作为关键诊断依据：胰腺肿大 ：胰腺横径超出相邻门静脉直径的1.5倍以上。回声减低 ：胰腺实质呈弥漫性低回声，反映组织水肿。周围高回声脂肪 ：胰腺周围脂肪组织因炎症渗出和皂化形成明亮的“炎性光环”。腹腔积液 ：游离液体聚集于网膜囊或腹腔最低处。 这一标准化体系的建立，将极大提升我国兽医对犬急性胰腺炎的诊断一致性与准确性。图1：LFA-1介导的白细胞粘附过程及夫扎普拉迪钠的作用位点示意图三、PANOQUELL®-CA1：创新机制背后的科学原理（一）药品基本信息 PANOQUELL®-CA1（注射用夫扎普拉迪钠）是由石原商事株式会社研发的新型抗炎制剂，其活性成分为夫扎普拉迪钠（Fuzapladib Sodium），属于白细胞功能相关抗原1（LFA-1）激活抑制剂。该药已于2022年11月14日获得美国FDA条件批准（申请号141-567），用于治疗犬急性胰腺炎相关的临床症状，成为全球首个获此适应症批准的LFA-1靶向药物。 编号 项目 内容 1 药品通用名称 注射用夫扎普拉迪钠 2 商品名称 PANOQUELL®-CA1 3 剂型规格 冻干粉+专用稀释剂双瓶装：• 主药瓶含夫扎普拉迪钠14mg、甘露醇52.5mg、硫代硫酸钠21mg• 稀释剂瓶含3.9mL无菌稀释液（含1.8% w/v苯甲醇） 4 重悬后浓度 4 mg/mL 5 药理分类 LFA-1激活抑制剂 6 审批状态 已获美国FDA条件批准，暂未在中国注册上市 重要提示：根据中国《兽药注册办法》规定，境外已上市但境内未注册的兽药，仅可在具备资质的教学科研机构或经特别许可的临床试验中使用。临床应用前应充分告知主人并取得知情同意。（二）作用机制详解 犬急性胰腺炎的核心病理过程是中性粒细胞的过度募集与活化，它们释放大量蛋白酶和促炎因子，加剧胰腺损伤并推动炎症扩散。LFA-1（淋巴细胞功能相关抗原1）是表达于白细胞表面的关键整合素分子，它通过与血管内皮细胞上的ICAM-1配体结合，介导白细胞粘附、迁移并最终浸润至胰腺组织。 PANOQUELL®-CA1的作用机制可形象地理解为“踩下免疫系统的刹车”。其活性成分夫扎普拉迪钠能选择性结合LFA-1的特定构象，阻止其与ICAM-1的有效连接，从而中断白细胞穿越血管壁的关键步骤。这种“中性粒细胞拦截术”并非全面抑制免疫功能，而是精准阻断炎症级联反应的源头，有效控制局部炎症扩展，减轻组织破坏，并有助于预防多器官功能障碍的发生。（三）药代动力学特征 基于比格犬开展的GLP合规安全性研究，获得了PANOQUELL®-CA1的主要药动学参数。结果显示，该药在静脉注射后表现出良好的药代行为： 参数 定义 数值（均值±SD） C₀ (μg/mL) 静脉注射后零时推算血浆浓度 3.55 ± 1.17 AUCₛₛ (h·μg/mL) 稳态下给药间隔内的曲线下面积 19.2 ± 12.7 T₁/₂ (小时) 终末消除半衰期 7.32 ± 4.08 Vss (L/kg) 稳态分布容积 0.216 ± 0.070 Clss (L/h/kg) 稳态清除率 0.026 ± 0.009 该药半衰期约为7.3小时，支持每日一次给药方案。其稳态暴露量（AUC）随剂量增加呈大于比例增长趋势，且连续给药9天后积累比率较低（约1.35–1.37），表明其体内蓄积风险较小。此外，该药为高蛋白结合率药物，需警惕与其他高蛋白结合药物潜在的相互作用。四、标准治疗方案与中国临床适配建议（一）推荐治疗参数 PANOQUELL®-CA1的标准治疗方案基于编号为AH0027的前瞻性、随机、双盲、安慰剂对照的现场研究结果制定。该研究共纳入61只确诊急性胰腺炎的犬，最终36只完成有效性分析，证实了其合理的疗效预期。 项目 国际标准 中国临床建议 剂量 0.4 mg/kg 同左，须依据实际体重精确计算 给药体积 0.1 mL/kg 建议使用1mL或3mL注射器精确量取，避免误差 途径 静脉注射（IV） 优先选择前肢头静脉，操作轻柔，避免关节附近穿刺 疗程 连续3天 不建议延长疗程，以规避累积毒性风险（二）药物配制操作规范必须使用原厂配套稀释剂 （含苯甲醇），严禁替换为生理盐水或其他溶媒； 将全部3.9mL稀释剂注入主药瓶，轻柔旋转直至冻干粉完全溶解，形成澄清溶液； 若溶液出现浑浊、沉淀或变色，则禁止使用； 多次使用时，剩余药液应在2–8°C避光保存，并于24小时内用完。（三）联合支持治疗 PANOQUELL®-CA1为靶向抗炎治疗，必须与全面的支持疗法相结合才能发挥最佳效果。以下是适用于中国多数宠物医院的标准支持方案： 治疗模块 推荐方案 中国常用替代选项 液体复苏 乳酸林格液或生理盐水，按脱水程度补液 同左，注意电解质监测 止吐治疗 马罗匹坦（Cerenia®）1 mg/kg SC q24h 若 unavailable，可用昂丹司琼0.5 mg/kg IV q8–12h 镇痛管理 芬太尼贴剂或恒速输注阿片类药物 哌替啶2–5 mg/kg IM q4–6h（注意呼吸抑制） 营养支持 早期肠内营养（EN），首选鼻饲管喂食 若无法建立EN，采用TPN支持（葡萄糖+氨基酸+脂肪乳） 并发感染防控 根据培养结果选用抗生素 初始经验性用药可选头孢曲松（20–30 mg/kg IV q24h）五、康复管理与预后评估（一）住院期间监测指标 在PANOQUELL®-CA1治疗期间，应动态监测以下指标以评估治疗响应与整体状况：MCAI评分 ：每日评估改良犬类活动指数（MCAI），包括活动、食欲、呕吐、腹痛、脱水、粪便稠度和大便带血七项内容，总分下降提示临床改善。炎症标志物 ：定期检测cPLI、C反应蛋白（CRP）、血清淀粉样蛋白A（SAA）水平，追踪炎症消退趋势。多器官功能 ：采用犬急性胰腺炎临床严重程度指数（CAPCSI）评估心脏、呼吸、肠道完整性和血管张力，及时发现并发症。血液学与生化 ：监测全血细胞计数、凝血功能、肝肾功能等，识别贫血、DIC、肝肾损伤等继发问题。（二）出院随访计划 建立完善的出院随访制度对于预防复发至关重要： 时间点 推荐措施 临床意义 第7天 电话回访食欲、排便、活动状态 早期发现复发迹象 第30天 复查cPLI与腹部超声 评估胰腺恢复情况，排除慢性化可能 长期 建立患者档案，记录每次发作诱因与治疗响应 推动慢性胰腺炎的全程管理 建议指导主人严格控制饮食，避免高脂食物，维持理想体重，并根据犬种和健康状况制定个性化的驱虫与疫苗接种计划。六、不良反应监测与处理措施（一）常见不良反应对比表 在包含61只犬的现场研究中，夫扎普拉迪钠组（n=31）与赋形剂对照组（n=30）的不良反应发生率对比如下： 类型 夫扎普拉迪钠组 对照组 提示意义 厌食 5例 (16.1%) 2例 (6.7%) 叠加效应，需加强营养支持 消化道疾病 5例 (16.1%) 3例 (10.0%) 包括呕吐、腹泻、肠炎等 肝炎/黄疸 4例 (12.9%) 2例 (6.7%) 提示肝功能监测必要性 心脏骤停 2例 (6.5%) 0例 极罕见，多见于重症病例 高血压（≥160mmHg） 6例（实验室研究） 0例 实验室研究发现，需血压监测（二）严重不良事件应急处理面部肿胀/过敏反应 ：立即停药，保持气道通畅，静脉给予地塞米松（0.1–0.2 mg/kg）或肌肉注射肾上腺素（0.01 mg/kg）。癫痫发作 ：立即停药，咪达唑仑0.2 mg/kg IV止惊，转入ICU监护，确保呼吸循环稳定。注射部位瘀伤 ：更换注射部位，局部冷敷处理，加强无菌操作规范。（三）禁忌与注意事项禁忌人群 ：对夫扎普拉迪钠或任何辅料过敏者禁用。慎用人群 ：尚未在患有心脏病、肝衰竭、肾功能损害、妊娠、哺乳或用于繁殖的犬中进行评估，应避免使用。特殊防护 ：由于缺乏致畸性数据，孕妇、哺乳期妇女或计划怀孕者应避免直接接触本品。药物相互作用 ：该药为高蛋白结合率药物，与其他高蛋白结合药物（如NSAIDs、华法林类）联用的风险未知，应谨慎合用。七、结语：迈向精准化胰腺炎管理新时代 PANOQUELL®-CA1代表了犬急性胰腺炎治疗领域的一项重要突破。其独特的LFA-1抑制机制，填补了传统支持疗法之外的空白，为控制炎症源头提供了科学依据。基于严谨的临床研究，该药展现出统计学显著的症状改善能力（p=0.0193），并拥有可接受的安全边际。 展望未来，我们呼吁进一步加强cPLI检测在全国范围内的普及，推广《犬急性胰腺炎超声诊断技术》（NY/T 4824—2025）等行业标准的应用，全面提升我国宠物医生对该病的早期识别与规范化诊疗水平。同时，期待PANOQUELL®-CA1能尽快进入中国的注册审评程序，让更多患犬受益于这一前沿科技成果。唯有将国际先进药物研发成果与本土临床实践深度融合，方能真正实现“以患者为中心”的高质量医疗服务目标。 它不会说话，但每一个异常都可能是无声的求救。您无需独自焦虑猜测，科学应对的第一步，从读懂它开始。 “宠医AI问诊知识库”现已免费开放，为您提供： 即时症状分析：输入“炸毛”、“拉稀”、“不吃不喝”，获取科学行动指南。 日常养护百科：从饮食配比到环境丰容，覆盖全生命周期健康管理。 紧急情况预判：识别危险信号，帮您把握送医黄金时间。 专业知识桥梁：为您与🐦医的高效沟通做好准备，让每次就诊都更有价值。 我们相信：预防，是最高级的医疗；观察，是最深情的告白。您的每一次科学选择，都在为它的生命质量投票。 现在就开始，用科学守护它的一生。免费使用，即刻开启科学养护之旅。